DocWire News Editors

DocwireNews

The majority of patients with diffuse large B-cell lymphoma (DLBCL) would have been eligible for treatment with chimeric antigen receptor (CAR) T-cell therapy, according to the results of a single center retrospective study presented at the 60th ASH Annual Meeting and Exposition.Patients with DLBCL who experience relapse or refractory disease may undergo treatment with hematopoietic cell transplantation, but about 50% of patients are ineligible because of a lack of response to chemoimmunotherapy or comorbidities. For these patients, CAR T-cell therapy may be an alternative treatment option, but real-world data are lacking on the use of CAR T-cell therapy in patients with DLBCL.Researchers led by Neil Bailey, MSc, of the Swedish Cancer Institute (SCI), Seattle, used electronic medical records to identify 486 patients with a recorded DLBCL diagnosis who had an outpatient visit at a SCI facility between January 1, 2014, and January 1, 2018. Of these patients, 60 had prior first-line anthracycline therapy at SCI and received second-line or beyond therapy at SCI.The investigators then determined CAR T-cell therapy eligibility based on inclusion and exclusion criteria from the ZUMA-1 clinical trial&mdash;an ongoing, multicenter, phase I/II study evaluating axicabtagene ciloleucel in patients with refractory, aggressive non-Hodgkin lymphoma. Forty-nine patients (82%) met all inclusion and exclusion criteria for CAR T-cell therapy. Patients had a median age of 61 years (range = 28&ndash;74 years) and received a median of three prior therapies; 23 patients (47%) had undergone transplant as second-line or subsequent therapy.Patients deemed eligible for CAR T-cell therapy had an overall survival (OS) of 37.1% at 24 months. At 24 months, CAR T-cell eligible patients who underwent transplant in the second-line or subsequent setting had significantly better OS compared to those who did not (61.6% vs. 12.0%; P&lt;.001).The findings suggest &ldquo;that the majority of the patients with relapsed or refractory DLBCL in the real world may have an opportunity to receive CAR T-cell therapy,&rdquo; according to the researchers.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

CAR T-Cell Therapy Viable Option for Majority of Real-World DLBCL Patients

ASH Annual Meeting 2018

The majority of patients with diffuse large B-cell lymphoma (DLBCL) would have been eligible for treatment with chimeric antigen receptor (CAR) T-cell therapy, according to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe